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Colorectal cancer (CRC) is one of the most common 
cancers, affecting 3 - 5% of the population, with 
an incidence peak in the age range 50 - 70 years. 
CRC is the third leading cause of cancer death in 
both men and women worldwide, and continues 
to be one of the most common fatal types of cancer. Worldwide, 
approxi mately 1.5 million individuals are diagnosed with CRC 
and 500 000 die from the disease annually.[1] Among Eurasian 
countries, Kazakhstan has the seventh-highest incidence of CRC.
CRC develops slowly over several years and progresses 
through cytologically distinct benign and malignant stages of 
growth, ranging from single-crypt lesions through adenoma 
to malignant carcinoma with the potential for invasion and 
metastasis. The majority of CRC cases are sporadic, with 20 - 
30% being familial.[1]
The classic model of colorectal tumourigenesis includes several 
genetic changes that are required for cancer initiation and progression. 
The earliest genetic trigger is the inactivation of the APC pathway. 
Mutations in other tumour suppressor genes (APC, SMAD2, SMAD 4, 
DCC, TP53) and oncogenes (K-ras) and several other genes/pathways 
accompany the transition of the tumour towards malignancy and 
metastasis. In addition to the gene mutations, deregulated expression 
of oncogenes and/or tumour suppressor genes can also be mediated 
via epigenetic modifications such as DNA methylation and histone 
acetylation. Rapidly developing insights into the molecular genetics 
of CRC have led to the identification of predictive and prognostic 
biomarkers for CRC.[2]
K-ras proto-oncogene and TP53 tumour suppressor gene mutations are 
among the most common genetic alterations in advanced colorectal 
tumours. The Ras genes code for a family of membrane-bound 
small guanosine triphosphate-bound proteins that play a key role in 
the transduction of extracellular mitogenic signals. Constitutively 
activating Ras mutations are present in a significant proportion of 
colorectal adenomas and carcinomas.[1-2] Approximately 40% of CRCs 
harbour K-ras mutations, 90% of which occur in codons 12 and 13; 
these mutations occur less frequently in codons 61, 63, and 146. 
Mutations in any of these codons lead to a constitutively activated RAS 
protein.[3-6] The relationship between K-ras mutations and the clinical/
morphological parameters of CRC has been extensively investigated. 
Some epidemiological studies show a prevalence of K-ras codon 12 
mutations over mutations in codon 13 in CRC tumours.[7] A study 
of more than 1 000 colorectal cancers showed that K-ras codon 12 
mutations (in particular c35G>T, pG12V), but not codon 13 mutations, 
are associated with poor prognosis in wild-type CRCs.[3] The prognostic 
value of codon 12 mutations was revealed in a functional study that 
showed that malignant transformation of NIH3T3 cells with mutant 
codon 12 K-ras had a more aggressive phenotype when compared with 
mutant codon 13 K-Ras.[3] A recent study of Chinese CRC patients 
revealed that a high frequency of codon 12 K-ras mutations was 
associated with poorly differentiated tumours, liver metastasis and 
poor survival.[6] Although the role of K-Ras mutations in tumour tissues 
is widely accepted to be associated with poor prognosis and anti-
epidermal growth factor receptor (EGFR) therapy,[4,12] the predictive 
value of K-ras mutations in blood samples remains uncertain.
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The TP53 gene product is a nuclear phosphoprotein that is expressed 
at low levels in most normal tissues and plays a key role in the 
control of cell cycle progression, genome stability and apoptosis. 
TP53 is one of the most frequently mutated genes in human cancers. 
Somatic mutations of TP53 are associated with more advanced stages 
of the disease, with loss of TP53 gene heterozygosity being a marker 
for the conversion of adenoma to carcinoma. In CRC tumours, more 
than 50% of mutations occur in the TP53 gene. The most common 
mutations are single-base substitutions that alter protein function. 
However, in contrast to the activating K-ras gene mutations, which 
are concentrated in only a few positions, mutations in the TP53 
gene are scattered over a large region of the gene.[8] Most TP53 gene 
mutations in CRC tumours occur in exons 5 - 9, which contain 
four highly conserved domains that are important in the clinical 
outcome of CRC and have been associated with increased malignant 
potential.[8,9] TP53 mutations occur with a higher frequency in distal 
colon and rectal tumours and with a lower frequency in proximal, 
mucinous and microsatellite instability-positive CRCs. Alterations to 
this gene are likely to have very little or no prognostic significance in 
CRC patients treated with surgery alone, but may be associated with 
marginally worse survival for patients treated with chemotherapy. 
There is some evidence that different TP53 mutations are associated 
with different clinical properties, including prognosis and response to 
therapy. TP53 status appears to have predictive value for the survival 
benefit of CRC patients on 5-fluorouracil (5FU) chemotherapy.[10]
Several studies have reported combined mutations in K-Ras and 
TP53 genes in CRC tumours,[7] but the clinical usefulness of K-ras 
and/or TP53 gene mutations is still somewhat controversial. The 
data on K-ras and TP53 aberrations and their relationship to patient 
survival and prognosis are insufficient to recommend the use of 
such mutations as prognostic indicators.[9] It is therefore clear that 
prospective studies to assess the prognostic utility of these genetic 
abnormalities are required. Although most reports indicate that 
altered K-Ras and TP53 genes in tumour tissues present at advanced 
stages, it would be interesting to assess the status of these genes 
in peripheral blood samples of CRC patients, because the gene 
heterozygosity can have a predictive value for determining prognosis.
The Kazakhstan National Screening Program for malignant 
neoplasms of the colon and rectum, initiated in 2011, showed that 
most cases were diagnosed at a very late stage when treatment is 
expensive and ineffective. The prediction of malignant potential and 
resistance to EGFR or 5FU chemotherapy at earlier stages of CRC 
development before surgery may improve patient survival.
Objective
Because the K-ras codon 12 and TP53 mutations are the most 
promising biomarkers of CRC tumour progression, the objective of 
this study was to assess K-Ras and TP53 gene status in blood samples 
of patients with advanced colorectal carcinoma.
Methods
Sampling
Blood samples were collected from 249 CRC patients at Almaty 
Oncology Centre, Almaty, Kazakhstan. Informed consent and detailed 
demographic information were obtained. Histological testing showed 
that 147 of these patients (59.0%) had presented with advanced CRC, 
and they were chosen as subjects for this study. The study protocol 
was approved by the Ethics Committee of the Asfendiyarov Kazakh 
National Medical University.
DNA isolation
Genomic DNA was isolated from peripheral blood leucocytes of 
the 147 patients with advanced CRC (stages III and IV) using 
the standard phenol-chloroform method with modifications in 
the composition of the lysis buffer (0.2M sodium acetate and 1% 
sodium dodecyl sulphate, pH 8.0) and precipitated in ice-cold 
ethanol.[9] The quantity and quality of the DNA samples were 
evaluated spectrophotometrically using an Eppendorf BioPhotometer 
(Eppendorf, Germany), and they were stored at –20°C until required.
Detection of K-ras mutations in codon 12
All known nucleotide mutations in codon 12 were screened by 
polymerase chain reaction-restriction fragment length polymorphism 
(PCR-RFLP). One hundred nanograms of total DNA was amplified 
in a 20 μL reaction mixture containing 10 pM of each specific 
primer (sense-5ʹ-ACTGAATATAAACTTGTGGTAGTTGGACCT-3ʹ, 
anti-sense-5ʹ-TCAAAGAATGGTCCTGGACC-3ʹ), 10 mM of each 
deoxy nucleotide triphosphate (dNTP), 1 mM MgCl2, 0.5 KCl, 0.1% 
gelatin and 1 U Taq-polymerase (Sigma-Aldrich, USA). Denaturation 
was performed at 95oC for 5 minutes, followed by 40 cycles at 95oC 
for 30 seconds, at 54oC for 40 seconds and at 72oC for 1 minute, 
with a final elongation step at 72oC for 7 minutes.[11] Five microlitres 
of each PCR product (157 bp) was digested with 1 U MvaI (BstN1, 
ThermoScientific, USA) at 60oC for 3 hours. Digestion products were 
analysed on 1.4% agarose gels. The normal K-ras allele is indicated by 
the presence of a 114-bp fragment as opposed to the 143-bp fragment 
in the mutant K-ras allele. Heterozygotes display both the 143- and 
114-bp fragments.
Sequencing of exons 5 - 9 of the TP53 gene
Direct sequencing was used to screen for mutations in exons 5 - 9 
of TP53.[9] The PCR was performed in a final volume of 20 μL 
containing 50 ng template DNA, 1 × PCR buffer, 0.2 mM of each 
dNTP, 1.5 mM MgCl2, 0.4 μM of each primer (Table 1) and 0.5 U of 
FastStart Taq DNA polymerase using the Veriti Dx 96-well Thermal 
Cycler (Applied Biosystems, USA). PCR products were visualised by 
electrophoresis on 1.5% agarose gels.
PCR products were purified using Nucleofast 96-well PCR plates 
(Macherey-Nagel, Germany). Sequencing reactions were performed 
Table 1. The PCR amplification primers and parameters used for direct sequencing of TP53 exons 5 - 9




Length of PCR 
products
Exons 5 - 6 f-TGTTCACTTGTGCCCTGACT
r-TTAACCCCTCCTCCCAGAGA
1 cycle of 2 min at 94°C, 20 cycles (94°C 
for 30 s, 63°C for 45 s with –5°C per cycle, 
72°C for 1 min), followed by 30 cycles 
(94°C for 30 s, 60°C for 45 s, 72°C for 
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using specific primers and the BigDye 
Terminator v3.1 sequencing kit (Applied 
Biosystems) and an ABI 3730xl Genetic 
Analyser (Applied Biosystems). The cycle 
sequencing reactions contained 50 - 
100  nmol of purified PCR product, 2 μl of 
BigDye Terminator, 1  μL of Sequencing 
Buffer and 3.2 pmol of primer in a total 
volume of 20 μL. Cycle sequencing was 
per formed using 55 cycles at 96°C for 
5  minutes, 60°C for 5 minutes and 96°C 
for 5 minutes. After cycle sequencing, 
sodium dodecyl sulphate was added and the 
samples were purified on Sephadex columns 
using a Tecan EVO150 robotic workstation 
(Agilent Technologies, USA). The purified 
sequencing products were dried, suspended 
in Hi-Di (Life Technologies, USA) and 
denatured at 95°C for 2 minutes before 
sequencing electrophoresis. Electrophoresis 
was performed on an ABI 3730xl using a 
50 cm capillary array and POP7 (Applied 
Biosystems).
DNA sequencing data were analysed 
using ChromasPro version 1.7.4 software, 
confirmed by reverse sequencing and com-
pared with the Leiden Open Variation and 
Universal Mutation databases to search for 
mutations.
Statistical analysis
Student’s t-test was used to compare the 
distribution of variables between groups, 
with a p-value of <0.05 considered signi-
ficant.
Results
Characteristics of the study 
population
Adenocarcinoma was the predominant 
tumour type among the 249 CRC patients 
first diagnosed with CRC in the period 
2012 - 2014, and 55.8% of the tumours were 
well or moderately differentiated. Table 2 
summarises the data on tumour localisation 
and stage, showing that rectal tumours 
predominated at 47.7% of all sites.
For the analysis of K-ras codon 12 
mutations and TP53 exons 5 - 9 mutations 
as potential markers of cancer progression, 
the advanced carcinoma cases were chosen 
after histological verification. A total of 147 
patients (59.0%) had advanced CRC (stages 
III and IV by TNM criteria). In this cohort 
there were 73 women (49.7%) and 74 men 
(50.3%), and the ethnic distribution was as 
follows: Kazakhs n=39 (26.5%), Russians 
n=86 (58.5%), other Asians (Turks, Uzbeks, 
Tatars, Uighurs, Koreans, Dungans) n=17 
(11.6%), and other Caucasians (Armenians, 
Ukrainians, Belarusians, Germans) n=5 
(3.4%). There were 50 cases of rectal cancer 
(34.0%) and 97 of colon cancer (66.0%), with 
126 cases of stage III cancer (85.7%) and 21 
of stage IV cancer (14.3%). Among patients 
suffering from advanced CRC there were 5 
smokers (3.4%), 14 ex-smokers (9.5%), and 
128 non-smokers (87.1%).
K-ras mutations in codon 12 in 
patients with advanced CRC
The 147 selected CRC patients with 
advanced carcinoma were screened for 
K-ras codon 12 mutations (Gly12Asp 
(GGT→GAT), Gly12Ala (GGT→GCT), 
Gly12Val (GGT→GTT), Gly12Ser 
(GGT→AGT), Gly12Arg (GGT→CGT), 
Gly12Cys (GGT→TGT)).
The genotyping data for the K-ras 
codon 12 mutations (Fig. 1) revealed 79 
heterozygous individuals (53.7%), while 68 
(46.3%) of the patients were homozygous 
wild type. Some differences were observed 
in the stage of cancer progression between 
individuals who were mutant heterozygous 
and normal homozygous for K-ras codon 
12 (Table 3). The percentage of patients 
who had progressed to stage IV was higher 
among the mutant allele carriers than 




TNM stage, n (%)
I II III IV
Rectum 115 (47.7) 8 (3.2) 44 (17.7) 48 (19.3) 15 (6.0)
Colon 48 (19.3) 3 (1.2) 14 (5.6) 21 (8.4) 10 (4.0)
Cecum 18 (7.5) 0 (0) 7 (2.8) 7 (2.8) 4 (1.6)
Sigmoid 57 (22.9) 5 (2.0) 17 (6.8) 28 (11.2) 7 (2.8)
Rectosigmoid 11 (4.6) 0 (0) 4 (1.6) 4 (1.6) 3 (1.2)
Total 249 (100.0) 16 (6.4) 86 (34.5) 108 (43.4) 39 (15.7)
Fig. 1. Genotyping of the K-ras codon 12 mutations. Blood DNA was isolated and subjected to PCR 
amplification, digestion with the restriction MvaI (BstN1) and separation of the digestion products on 
3% agarose gels as described under ‘Methods’. The 114-bp fragment indicates the normal K-ras while 
the 143-bp fragment indicates the mutant K-ras codon 12 allele. Lane M is a 100-bp DNA ladder, 
while lanes 1, 4, 6 and 8 are the undigested 157-bp PCR products; lanes 2, 5 and 9 show the normal 
homozygous individuals represented by the 114-bp band, while lanes 3, 7, 10, 11, 12 and 13 show 
the heterozygous individuals. The gel shows only a sample of 13 of the 147 patients with advanced 
carcinoma investigated in this study.
Table 3. Differences in the stage of CRC 
in individuals with homozygous and 






53 (67.1 ) 26 (32.9)
Normal 
homozygous, n (%)
58 (85.3) 10 (14.7)
Odds ratio 1.25 1.76
p-value >0.05 >0.05
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among the normal homozygotes (32.9% v. 
14.7%).
The heterozygous genotype was present 
in 50% of patients with rectal tumours and 
in 50% of those with colon tumours. Most 
of the normal homozygotes were diagnosed 
with colon tumours (84.6%), and only 15.4% 
with rectal tumours. These differences were 
statistically significant (for colon tumours 
odds ratio (OR) 2.7; p<0.01 and for rectal 
tumours OR 2.84; p<0.01).
The prevalence of Caucasians among 
mutant allele carriers (70% Russians and 
other Caucasians), and the prevalence of 
Asians among normal homozygotes (53.9% 
Kazakhs and other Asians) were observed as 
significant (for Caucasians OR 2.09; p<0.05 
and for Asians OR 2.32; p<0.05).
The percentage of smokers and ex-smokers 
among heterozygotes was 13.4%, while 
among normal homozygotes there were only 
ex-smokers (11.5%). Distribution by gender 
was similar between heterozygotes (40 males 
and 39 females) and normal homozygotes 
(34 males and 34 females).
Analysis of TP53 mutations
No TP53 exon 5 - 9 mutations were 
observed by direct sequencing, as shown in 
Fig. 2. However, three cases of nucleotide 
replacements were noticed in intron 9 
(c.993+12T>C) (Fig. 2, A), and another 
two cases in intron 4 (c.376-19C>T, Fig.  2, 
B), all in the heterozygous state. Table 4 
summarises the DNA sequencing data in 
individuals with TP53 mutations. Two 
different types of mutations were detected 
in five patients from among the 147 patients 
with advanced carcinoma.
Discussion
It is well known that mutations in the 
tumour suppressor gene TP53 and K-ras 
oncogene are not responsible for initiation of 
the development of CRC, but are critical for 
tumour progression and metastasis.[1-2,8-9,12]
The most common TP53 gene mutations 
are single-base substitutions that alter 
protein function. While loss-of-function 
mutations are generally inherited or early 
events, some of the oncogenic mutations that 
confer gain-of-function properties are late-
stage events, mostly exon 5 - 9 mutations, 
that play an important role in the clinical 
outcome of CRC.[1,9]
Our study on peripheral blood samples 
of 147 patients with advanced CRC did 
not show any significant changes in TP53 
exon 5 - 9 mutations, except for two novel 
heterozygous nucleotide replacements in 
the non-coding regions of the gene. One 
change in intron 4 (c.376-19C>T) was 
observed in two patients, and another 
nucleotide substitution was detected in 
intron 9 (c.993+12T>C) in three patients. 
No information on the significance of these 
mutations detected in CRC patients from 
Kazakhstan is available in the literature. It 
should also be noted that the TP53 mutations 
were examined in the peripheral blood DNA 
of the patients and not in the tumours; these 
are therefore inherited mutations. However, 
it cannot be ruled out that additional genetic 
events may occur along the way. Although 
intronic mutations do not alter the amino 
acid sequence of a gene product, they can 
influence the regulation of gene activity by 
altering the binding of regulatory proteins 
or miRNA, leading, for example, to aberrant 
splicing (IARC TP53 Database).
The most common K-ras codon 12 muta-
tions result in the substitution of glycine for 
valine, thus changing the spatial conforma-
tion of RAS, leading to a consti tutively 
activated form where the RAS signalling 
cascade to other partici pants occurs 
regardless of EGFR status. This explains 
why the predictive value of K-ras mutations 
in determining whether or not patients will 
respond to anti-EGFR therapy is of much 
interest.[13,14]
Screening of all known K-ras codon 12 
mutations (Gly12Asp, Gly12Ala, Gly12Val, 
Gly12Ser, Gly12Arg, Gly12Cys) in the blood 
DNA of 147 CRC patients with advanced 
CRC showed heterozygous mutations in 
more than 50% of the patients (79/147). Our 
data are in agreement with the published 
data showing K-ras codon 12 mutation 
frequencies ranging from 30% to 60% 
in tissue samples from rectal and colon 
tumours.[10,13-14]
We could not find any significant 
differences regarding gender, age or smoking 
habit between patients carrying the K-ras 
codon 12 mutation and the wild-type 
homozygotes. The percentage of patients 
with stage IV cancer carrying the mutant 
allele was higher than among the normal 
homozygotes (32.9% v. 14.7%), but this was 
not statistically significant. Tumours of the 
rectum and colon were equally distributed 
among heterozygous patients; however, the 
prevalence of colon tumours (84.6%) in 
normal homozygous patients was statistically 
significant. The relationship between K-ras 
mutations and the clinical/morphological 
parameters of CRC has been extensively 
investigated.[5] There is some evidence that 
K-ras codon 12 mutations are significantly 
Table 4. Nucleotide changes detected by direct PCR sequencing TP53 exons 5 - 9 




TP53 9i c.993+12T>C, 
rs1800899
One female (born 1967), rectal, stage III T3NxMo
One male (born1937), rectal, stage IV T3NxM1
One male (born1937), colon, stage IV T3NoM1
TP53 4i c.376-19C>T One female (born 1983), rectal, stage III T4NxMo
One female (born1952), colon, stage IV T4NxM1
C T G YT C CT T T G T C T Y G G G A
A.   Heterozygous T/C substitution
       in intron 9 (c.993+12T>C)
B.   Heterozygous T/C substitution
       in intron 4 (c.376-19CT>T)
Fig. 2. DNA sequence analysis of the TP53 gene. Blood DNA was isolated and subjected to PCR 
amplification using the primers defined in Table 1, and the PCR products were subjected to direct 
sequence analysis. A: Nucleotide change observed in intron 9 in three patients; B: Nucleotide change 
observed in intron 4 in two patients.
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associated with poor survival at all stages of cancer progression. 
Estimated event-free survival correlates with poor tumour 
differentiation status, pericolic fat invasion and metastasis.[5] CRCs 
with K-ras mutations are associated with distinctive morphological 
features. K-ras codon 12 mutations are more frequently observed in 
carcinomas of the proximal-distal axis of the colorectum, mucinous 
differentiation, and contiguous polyps. Our findings are in agreement 
with these findings.
Some ethnic differences were observed in the Kazakhstan patients: 
there was a higher prevalence of mutant allele carriers among 
the Caucasians (Russians and others) and a higher prevalence of 
normal homozygotes among the Asians (Kazakhs and others). It is 
well established that ethnic differences and lifestyle have a strong 
influence on the frequency of K-ras mutations.[15] K-ras codon 12 
mutation is a good biomarker in stage IV CRC, predicting lack 
of benefit from the anti-EGFR targeted antibodies cetuximab 
(Erbitux) and panitumab (Vectibix).[4,15] It is possible that the 
findings on K-ras codon 12 carriers in our population will help in 
the choice of adjuvant therapy.
Several studies have detected compound mutations in the K-ras 
and TP53 genes in CRC.[4,15] A Tunisian CRC study reported the 
detection of a K-ras somatic mutation in 31.5% of patients, with 
81.2% having a single mutation at codon 12 and 23% having a single 
mutation at codon 13; 43.75% of the patients harboured combined 
K-ras and TP53 mutations, with 71.42% of them showing TP53 
over-expression.[7] In our study two of the five patients (a woman 
born in 1967, rectal carcinoma, stage III T3NxMo, and a man born 
in 1937, rectal carcinoma, stage IV T3NxM1) with TP53 intron 
mutations were also heterozygous for the K-ras codon 12 mutation. 
In both cases the mutation was in intron 9 of TP53 (c.993+12T>C). 
Because the percentage of TP53 mutations among advanced CRC 
patients from Kazakhstan is very low (3.4%) and nothing is known 
about the pathological significance of these intronic mutations, there 
is no evidence for an association with poor prognosis. However, 
our observation of the prevalence of inherited K-ras codon 12 
mutation carriers in advanced CRC patients (53.7%), together with 
the literature data, supports the idea that these mutations may be a 
predictive marker of cancer progression and anti-EGFR therapy.
Conclusion
The study demonstrates that the analysis of peripheral blood 
samples of patients suffering from advanced CRC may have 
prognostic value only for K-ras codon 12 mutations, and not for 
TP53 mutations. 
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